Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations
NCT05810740
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
37
Enrollment
INDUSTRY
Sponsor class
Conditions
Melanoma
BRAF V600 Mutation
Unresectable Melanoma
Metastatic Melanoma
Interventions
DRUG:
Binimetinib 15 MG
DRUG:
Binimetinib 45 MG
Sponsor
Pierre Fabre Medicament
Collaborators
[object Object]